Search
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16918ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
Zosuquidar
go.drugbank.com/drugs/DB06191InvestigationalIt is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Crotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedBites from this snake are the most common in the state of Texas, USA [A33157]. … The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F113].
4-nitrophenyl-beta-D-galactoside
go.drugbank.com/drugs/DB02632ExperimentalCategories: Compounds used in a research, industrial, or household settingRemacemide
go.drugbank.com/drugs/DB06458ExperimentalCategories: Compounds used in a research, industrial, or household settingPlatelet Lysate
go.drugbank.com/drugs/DB15869InvestigationalBecause white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.
CTCE-0214
go.drugbank.com/drugs/DB05934ExperimentalCTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalSimilar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer … Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE).
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Paritaprevir as a first line … Depending on the genotype, Paritaprevir is often used in combination with other antivirals such as [DB09296], [DB09183], [DB00503], and [DB00811], with the intent to cure, or achieve a sustained virologic
Synonyms: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrroloMirococept
go.drugbank.com/drugs/DB06492ExperimentalIt consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation